Acumen Pharmaceuticals, Inc. (ABOS) News
Follow Acumen Pharmaceuticals, Inc. (ABOS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Acumen Pharmaceuticals Is Maintained at Buy by Citigroup
Ratings actions from Benzinga: GMT) Acumen Pharmaceuticals Price Target Raised to $5.00/Share From $4.00 by CitigroupRatings actions from Benzinga
NEWS | Sep 15, 2026, 04:30 PM UTC
L
Acumen Pharmaceuticals to hold virtual investor day on September 16, 2026
Acumen Pharmaceuticals said it will hold a virtual investor day on September 16, 2026. The announcement comes from the company and refers to its clinical-stage biopharmaceutical work in Alzheimer’s disease.
EQUITY | Sep 10, 2026, 08:01 PM UTC
L
Acumen Pharmaceuticals to hold virtual investor day Sept. 16, 2026
EQUITY | Sep 10, 2026, 08:00 PM UTC
L
ABOS: Phase IIb Alzheimer's data and advanced brain delivery program set stage for future breakthroughs
The conference highlighted a robust Alzheimer's pipeline, with phase IIb data for sabirnetug expected late this year and a novel EBD program targeting enhanced brain delivery. Strong trial execution, positive KOL feedbac
EQUITY | Sep 10, 2026, 02:14 PM UTC
L
ABOS: Phase II trial of sabirnetug targets toxic oligomers in Alzheimer's, with pivotal data due late 2026
The conference highlighted a rapidly growing Alzheimer's market and detailed the phase II ALTITUDE-AD trial of sabirnetug, targeting toxic A-beta oligomers with data expected in late 2026. Strong KOL support, robust tria
EQUITY | Sep 10, 2026, 01:42 PM UTC
L
ABOS: Phase II data for a novel Alzheimer's antibody is expected in Q4 2024, with EBD IND in 2027
Sabirnetug, a selective A-beta oligomer antibody, is in phase II for early Alzheimer's, with data expected in late 2024. The Enhanced Brain Delivery program, leveraging JCR's technology, targets an IND in mid-2027. Key m
EQUITY | Sep 09, 2026, 10:09 PM UTC
L
ABOS: Phase II data for a novel Alzheimer's antibody and brain delivery tech are expected by Q4 and 2027
The discussion highlighted progress on sabirnetug, a selective Aβ oligomer antibody for early Alzheimer's, with phase II data expected in Q4. The Enhanced Brain Delivery program, leveraging JCR's technology, aims for an
EQUITY | Sep 09, 2026, 09:18 PM UTC
L
ABOS - Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
ABOS - Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 08:00 PM UTC
L
ABOS Reports Q2 2026 Financial Results
ABOS reports second quarter 2026 financial results and business highlights
EARNINGS | Aug 12, 2026, 11:00 AM UTC
L
ABOS - Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
ABOS - Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
EARNINGS | Aug 05, 2026, 08:00 PM UTC
L
ABOS Acumen Pharmaceuticals - ebd bispecific antibodies show improved brain penetration compared to native anti-aβo antibodies - No hematolo
ABOS Acumen Pharmaceuticals - ebd bispecific antibodies show improved brain penetration compared to native anti-aβo antibodies - No hematological safety signals observed for acu401 in non-human primates
EQUITY | Jul 15, 2026, 11:30 AM UTC